Betagenon was granted 1,8 Meur from the Horizon 2020 SME Instrument programme, phase 2.
Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers.
This project aims to close the gap to the market for a small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novel first-in-class drug for the treatment of type 2 diabetes (T2D) and associated cardiovascular complications, including heart failure and peripheral arterial disease. The number of adults around the world with diabetes quadrupled from 108 million in 1980 to 422 million in 2014. None of the existing drugs, however, reduces insulin resistance - a primary cause of obesity-induced T2D. Betagenon has developed and pre-validated the first candidate AMPK activator drug in T2 diabetics, a key regulator of energy balance, both on a single cell level and the whole organism level. The project is strategically focused on performing a Phase II proof-of-concept validation of O304.
GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC.
“In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products. GAEU has taken the leading role in shaping strategies behind our proposal, which resulted in the total scoring of 14.64 out of 15 – an almost perfect proposal. Based on my experience in cooperating with GAEU, I strongly recommend them as Horizon 2020 advisors.”
Thomas Edlund, Ph.D., Prof. Founder, Chief Executive Officer.
Thomas Edlund Ph.D., Prof. Founder, Chief Executive Officer